Skip to content
CancerIndex

Publication

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

Authors not recorded

Cancer Res2006PMID 16818618stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
16818618
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
EGFR L858R1
NeratinibLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response3accepted
EID2628

In an in vitro study using NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R muta… (full text at CIViC)

PMID 16818618 · Shimamura et al., 2006 · Open in CIViC

civic
EGFR T790M1
NeratinibLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response2accepted
EID2162

The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 μmol/L). In an in vitro study Ba/F3 cells t… (full text at CIViC)

PMID 16818618 · Shimamura et al., 2006 · Open in CIViC

civic
ERBB2 G776INSV_G/C1
ErlotinibLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Resistance—submitted
EID4627

In an in vitro study, Ba/F3 cells expressing ERBB2 G776insV_G/C mutation demonstrated decreased sensitivity to erlotinib treatment (IC50: 0.28 umol/L vs. 0.009 umol/L) compared to Ba/F3 cells expressi… (full text at CIViC)

PMID 16818618 · Shimamura et al., 2006 · Open in CIViC

civic